The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • The variant label for this record ("m.7896G>A") does not appear to be in HGVS format
  • Despite there being a valid 'cspec' property in the messages there's a discrepancy in message contents and CSPEC data: * Message Gene: MT-CO2 CSPEC Genes: [] * Message MONDOs: MONDO:0044970 CSPEC MONDO: []
  • No CSPEC computed assertion could be determined for this classification!


Variant: m.7896G>A

CA120607

9662 (ClinVar)

Gene: MT-CO2
Condition: mitochondrial disease
Inheritance Mode: Mitochondrial inheritance
UUID: 94a077ec-d848-463a-8984-d3b77c44a083
Approved on: 2024-02-12
Published on: 2024-11-15

HGVS expressions

NC_012920.1:m.7896G>A
J01415.2:m.7896G>A
ENST00000361739.1:c.311G>A

Pathogenic

Met criteria codes 4
PS3_Supporting PM2_Supporting PVS1_Strong PM6_Supporting
Not Met criteria codes 4
BP4 PS2 PS4 PP3

Evidence Links 2

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Mitochondrial Disease Nuclear and Mitochondrial Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1_mtDNA

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Mitochondrial Diseases VCEP
The m.7896G>A (p.W104Ter) variant in MT-CO2 has been reported in one individual to date (PMID: 11558799), in a three-year-old child with psychomotor delay, failure to thrive, and cardiac hypertrophy from infancy who later developed cerebral atrophy and pigmentary retinopathy. Complex IV deficiency was noted in muscle. The variant was present at 76% heteroplasmy in muscle, 67% in blood, and 60% in fibroblasts. The variant was undetectable in blood from her mother and sister (PM6_supporting). There are no additional individuals reported with de novo occurrences of this variant to our knowledge. This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). There are no in silico predictors for this type of variant in mitochondrial DNA. This variant results in a significant truncation (52%) of the MT-CO2 protein (PVS1_strong). There were several compelling studies performed detailing functional validation (PS3_supporting). Activities and assembly of complexes I and IV (and of any COX-containing supercomplexes) were impaired in cybrid cell lines with the variant present at homoplasmy (PMID: 22342700). Single fiber testing showed higher levels of the variant in COX-deficient fibers (n = 9; 70.8 ± 8.1%) than in COX-positive fibers (n = 10; 17.6 ± 17.8%; p < 0.0001; PMID: 11558799). Immunoblot analysis in muscle from the proband revealed a 53% reduction of the COX II polypeptide and a 48% reduction of COX I polypeptide compared to controls (PMID: 11558799). In summary, this variant meets criteria to be classified as likely pathogenic for primary mitochondrial disease however, after extensive discussion, this Expert Panel elected to modify the classification to pathogenic given the compelling functional validation and variant type. We note that some experts on this panel felt likely pathogenic was the more appropriate classification. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on February 12, 2024. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PM6_supporting, PS3_supporting, PM2_supporting, PVS1_strong.
Met criteria codes
PS3_Supporting
There were several compelling studies performed detailing functional validation (PS3_supporting). Activities and assembly of complexes I and IV (and of any COX-containing supercomplexes) were impaired in cybrid cell lines with the variant present at homoplasmy (PMID 22342700). Single fiber testing showed higher levels of the variant in COX-deficient fibers (n = 9; 70.8 ± 8.1%) than in COX-positive fibers (n = 10; 17.6 ± 17.8%; p < 0.0001; PMID: 11558799). Immunoblot analysis in muscle from the proband revealed a 53% reduction of the COX II polypeptide and a 48% reduction of COX I polypeptide compared to controls (PMID: 11558799).

PM2_Supporting
This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting).
PVS1_Strong
This variant results in a significant truncation (52%) of the MT-CO2 protein (PVS1_strong).
PM6_Supporting
The variant was undetectable in blood from her mother and sister (PM6_supporting).
Not Met criteria codes
BP4
There are no in silico predictors for this type of variant in mitochondrial DNA.
PS2
The variant was undetectable in blood from her mother and sister (PM6_supporting).
PS4
The m.7896G>A (p.W104Ter) variant in MT-CO2 has been reported in one individual to date (PMID: 11558799), in a three-year-old child with psychomotor delay, failure to thrive, and cardiac hypertrophy from infancy who later developed cerebral atrophy and pigmentary retinopathy. Complex IV deficiency was noted in muscle. The variant was present at 76% heteroplasmy in muscle, 67% in blood, and 60% in fibroblasts.
PP3
There are no in silico predictors for this type of variant in mitochondrial DNA.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.